In Reply We are in agreement that adenosine-sensitive ventricular tachycardia (VT) is a possibility. Various idiopathic VTs, including outflow tract and fascicular VTs, can terminate with adenosine administration. Hence, termination of the tachycardia with adenosine alone would not be diagnostic, and other considerations, including the electrocardiogram and clinical situation, should be taken into account to help make the diagnosis. Finally, if an atrial arrhythmia continued without ventricular conduction due to atrioventricular block secondary to adenosine use, this would be confirmation of supraventricular tachycardia.

Joseph L. Schuller, MD
Paul D. Varosy, MD
Duy Thai Nguyen, MD

Author Affiliations: Department of Medicine, University of Colorado, Aurora (Schuller, Varosy, Nguyen); Denver Health Medical Center, Denver, Colorado (Schuller); VA Eastern Colorado Health Care System, University of Colorado, Colorado Cardiovascular Outcomes Research (CCOR) Group, Denver (Varosy).

Corresponding Author: Duy Thai Nguyen, MD, Department of Medicine, University of Colorado, 12401 E 17th Ave, Leprino Bldg, MS-132, Aurora, CO 80045-2548 (duy.t.nguyen@ucdenver.edu).

Conflict of Interest Disclosures: None reported.


Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Renal Outcomes: Prevalent User Designs May Overestimate Benefit

To the Editor The recent study by Hsu et al2 regarding the renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia is important but we believe that the findings should be interpreted with caution.

According to the way that angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) users were defined, people who had taken and then ceased ACEI/ARB therapy prior to the first erythropoiesis-stimulating agent (ESA) prescription would have been classified as nonusers. For a proportion of these participants, ACEI/ARB therapy may have been stopped for safety reasons, for example, to attempt to delay dialysis treatment. Indeed, 25% of those defined as nonusers received a prescription for ACEI/ARB in the 90 days prior to the first ESA prescription, and many “nonusers” had clear indications for ACEI/ARB therapy. This study design could create differential misclassification where those defined as ACEI/ARB users were more likely to have better kidney function or slower decline than those defined as nonusers. A “new user” design including all patients who initiate ACEI/ARB therapy rather than prevalent users may have led to less bias and provided a more balanced comparison.3

To draw an analogy, in a study of car driving and mortality risk among people 80 years and older, based on the design used by Hsu et al,1 we would classify people who do not currently drive as nondrivers, even if they had stopped driving in their 70s. Many of the people who had stopped driving in their 70s would have done so because of failing health and increased frailty. This group will, of course, be at high risk of dying. The study will find that driving is associated with marked survival benefits and might lead us to advocate driving as a way of living longer. The reality is that as people approach death they often decide it is time to stop driving. A better design would be to start observing people from when they commenced driving.

Although the authors used a propensity score analysis to try and ensure comparability between the groups, this cannot compensate for unmeasured confounders, such as rate of change of kidney function.4

The authors conclude that “withholding ACEI/ARB therapy is unwarranted and may hasten the onset of ESRD [end-stage renal disease].”5,6 We believe that the findings of this study are interesting but should not provide false reassurance about the effectiveness and safety of ACEI/ARB use in advanced chronic kidney disease.

Laurie Tomlinson, MBBS, MRCGP, PhD
Liam Smeech, MBChB, FRCP, FFPH, FRCP, PhD

Author Affiliations: Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, England.

Corresponding Author: Laurie Tomlinson, MBBS, MSc, PhD, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, England (laurie.tomlinson@lshtm.ac.uk).

Conflict of Interest Disclosures: None reported.


In Reply We appreciate the comments of Tomlinson and Smeech concerning that the differential misclassification would tend to bias our results toward favoring angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. We performed additional analyses to address the question raised in the letter. However, their speculation is not evidenced by the further analysis from our cohort.
To minimize the possibility of misclassification of those who had taken and then, for safety reasons, ceased ACEI/ARB therapy prior to the first erythropoiesis-stimulating agent (ESA) prescription as nonusers, we redefined the nonusers (the referent group) as those who have not ever been treated with an ACEI/ARB up to 3 months and 6 months before commencing ESA therapy, respectively. Our data showed that the adjusted hazard ratios (95% CIs) of chronic dialysis in ACEI/ARB users were 0.94 (0.91-0.97) and 0.95 (0.92-0.98), respectively, and of dialysis or death, 0.94 (0.91-0.96) and 0.95 (0.92-0.98), respectively. Similar results could also be observed in the multivariable models further adjusted for the propensity score. The delta sensitivity analyses suggest our previously published data that the hazard ratio of long-term dialysis or death for the ACEI or ARB users was 0.94 compared with nonusers was an unbiased estimate.

We acknowledge the “new user” design2 is a good method for pharmaco-epidemiological research. However, it may not be applicable to our study. In fact, the number of new ACEI or ARB users who had never used an ACEI or ARB at least 6 months prior to the first ESA prescription was only 1159 (8.2% of total ACEI or ARB users) in our cohort. The sample size was too small to secure a sufficient statistical power for the study. Few patients with advanced chronic kidney disease were also recognized to improve their renal function by stopping ACEI or ARB therapy in our study,3 and it has been mentioned in the small-scale observational study by Ahmed et al.4 However, our study and the study by Ahmed et al3 are not comparable and have differences in case number (28 497 vs 52), median follow-up period (7 vs 30 months) and study outcomes (70.7% dialysis and 20.0% death vs 9.6% dialysis and 9.6% death). Obviously, the medical conditions in our cohort were much more complex, indicating the beneficial impact of stopping ACEI/ARB therapy observed in the study by Ahmed et al3 is not generalizable to our study population.

In conclusion, we are confident in the validity of our study, and we also believe the observational study using a representative national database is one of the most feasible study designs for the predialysis hypertensive patients with advanced CKD. The implication of our study is to reassure that the renoprotective effect of ACEI/ARB use still exists in predialysis patients with advanced chronic kidney disease and “withholding ACEI/ARB therapy is unwarranted” for patients with advanced CKD unless indicated by clinical evidence.

Chih-Cheng Hsu, MD, DrPH
Jia-Sin Liu, MS
Der-Cherng Tarng, MD, PhD

Author Affiliations: Division of Geriatrics and Gerontology, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan (Hsu, Liu); Department of Health Services Administration, China Medical University and Hospital, Taichung, Taiwan (Hsu); Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (Tarng); Institutes of Physiology and Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (Tarng).

Corresponding Author: Der-Cherng Tarng, MD, PhD, Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan (dctarng@vghtpe.gov.tw).

Conflict of Interest Disclosures: None reported.


Improving Medication Adherence and Helping Patients Make Lifestyle Changes

To the Editor In the study by Cohen et al,1 the authors report no improvement in cardiovascular risk factors when dietitian or nurse-led education was provided to patients following acute coronary syndrome (ACS) compared with usual care. This study represents an alternative approach to standard educational interventions that could be provided through clinic-based cardiac rehabilitation (CR) following ACS.

Another major factor to consider when modifying CR services is medication adherence, as improvements in this behavior may predict further success with other, more complex lifestyle changes.2 In general, an adequate focus on medication adherence has only been achieved by more intense CR programs requiring a longer schedule of visits.2 The study by Cohen et al3 appeared to have a sufficient level of intensity and patient contact such that a pharmacist could have been included in order to assess and promote medication adherence.

As reported by Cohen et al,4 it appears that medication adherence in the study was high; however, they did not report the percentage of patients stopping all guideline-recommended medications. Only percentages for individual medications are presented, and this is an unusual and inadequate measurement for reporting medication adherence.3 Ho et al4 demonstrated that patients who stop using all medications by 1 month after discharge are 10% more likely to have died during the 12 months following ACS. Given the 12-month time frame of the study by Cohen et al3 and the multiple visits required in the intervention, we would have been interested to see more emphasis placed on additional measures of medication adherence and interventions seeking to improve it. We are currently conducting a study investigating the impact on medication adherence from pharmacist home visits following ACS to help address this issue.

Daniel D. L. Bernal, BPharm(Hons)
Luke R. E. Berezincki, BPharm(Hons), PhD
Gregory M. Peterson, PhD(Hons)

Author Affiliations: Pharmacy, School of Medicine, University of Tasmania, Sandy Bay, Tasmania, Australia.

Corresponding Author: Daniel D. L. Bernal, BPharm(Hons), Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, Sandy Bay 7001, Tasmania, Australia (daniel.bernal@utas.edu.au).

Conflict of Interest Disclosures: None reported.